THYROID FUNCTION TEST and RADIONUCLIDE THERAPY

Size: px
Start display at page:

Download "THYROID FUNCTION TEST and RADIONUCLIDE THERAPY"

Transcription

1 THYROID FUNCTION TEST and RADIONUCLIDE THERAPY Ajalaya Teyateeti, M.D. Division of Nuclear Medicine Department of Radiology

2 I. Thyroid function test OUTLINE Application and interpretation of in vitro TFT Principle, application and interpretation of in vivo TFT II. Radionuclide therapy in thyroid disease Indication, treatment and follow-up Hyperthyroidism and differentiated thyroid cancer III. Case demonstration

3 THYROID FUNCTION TEST Outline Thyroid anatomy Thyroid physiology Thyroid hormone synthesis Thyroid function tests

4 Thyroid anatomy Normal thyroid gland Anterior superior aspect of trachea just below the thyroid cartilage Two lobes and isthmus Normal weight 20 gm.

5 Thyroid anatomy Pyramidal lobe May be identified in some Extend toward hyoid bone Thyroglossal duct remnant

6 Thyroid physiology Hypothalamic-pituitary-thyroid axis Control function of thyroid gland Stimulating hormone : TRH, TSH Inhibiting hormone : T3 and T4 (convert to T3 by type II deiodinase)

7 Thyroid hormone synthesis Trapping of iodide (I - ) Oxidation : Change iodide to iodine (I) by peroxidase Organification : Iodination of thyroglobulin and forming MIT and DIT Coupling : Conjugation of MIT + DIT to form T3 and DIT + DIT to form T4 Thyroid hormone release

8 Thyroid hormone synthesis

9 Thyroid function test I. In vitro tests (clinical application) 1. Serum T3 and T4 2. Free T3 and free T4 3. Thyroid stimulating hormone (TSH) 4. Thyroglobulin (Tg) 5. Anti-thyroid antibody

10 1. Total T3 and T4 T3 More metabolically active than T4 Often useful to diagnose hyperthyroidism or to determine the severity of the hyperthyroidism T4 Include both bound and free forms Binds to circulating protein

11 2. Free T3 and Free T4 Free form = Active form Serum protein affect total T4 level Protein binding of T3 is 10 times less than T4 No significant difference between free T3 and total T3

12 3. Serum TSH Best initial and most sensitive test to evaluate thyroid function High TSH level indicates primary hypothyroidism Low TSH indicates primary hyperthyroidism

13 Common clinical application Status T3 T4 TSH Euthyroid Normal Normal Normal Hyperthyroidism 1 High High Low Subclinical Normal Normal Low Hypothyroidism 1 Low Low High Subclinical Normal Normal High

14 4. Thyroglobulin Protein precursor of thyroid hormone Made by normal thyroid cells or thyroid cancer cells Most reliable tumor marker for DTC following thyroidectomy and 131 I treatment Interfere with TgAb

15 5. Anti-thyroid antibody Thyroglobulin antibody (TgAb) Anti-microsomal antibody Thyroid peroxidase antibody (TPOAb) Thyroid stimulating hormone receptor antibody (TRAb) To diagnose and monitor autoimmune thyroid disease

16 Thyroid function test II. In vivo tests 1. Thyroid scan 2. Thyroid uptake 3. Diagnostic RAI whole body scan (Dx-WBS)

17 1. Thyroid scan Indications : To evaluate I. Cause of thyrotoxicosis II. Function of thyroid nodule III. Location of ectopic thyroid tissue IV. Cause of neonatal hypothyroidism V. Substernal goiter VI. Post-operative residual thyroid tissue/tumor

18 Radionuclide Tracer Advantages Disadvantages 123 I - Retrosternal goiter - No beta emission Ideal tracer 131 I - Same as 123 I with lower cost and more available - Higher cost - Less convenient (imaging 24 hr.) - Less available - Higher radiation (Beta) 99m TcO 4 - Less expensive - More available - More rapid examination (imaging 20 min.) - Trapped, not organified - Esophageal & vascular activity

19 1. Thyroid scan Imaging 131 I uci, oral Imaging at 24 hr. 99m Tc-pertechnetate 2 mci, IV Imaging at 20 min. Sternal notch

20 Normal thyroid scan Right lobe may be slightly larger. Amount of activity in isthmus is vary Salivary gland activity seen on 99m Tc-pertechnetate imaging 99m Tc-pertechnetate Background is higher in 99m Tc imaging

21 I. Evaluate causes of thyrotoxicosis Hyperthyroidism VS Thyroiditis Thyrotoxicosis - Hypermetabolic state resulting from excessive thyroid hormone due to hyperthyroidism or parenchymal destruction Hyperthyroidism - Overactive gland producing excessive hormone Graves disease, toxic MNG, toxic adenoma

22 I. Evaluate causes of thyrotoxicosis Graves disease Toxic MNG Toxic adenoma Sub-acute thyroiditis

23 II. Evaluate function of thyroid nodule Hot nodule Cold nodule Indeterminate nodule

24 II. Evaluate function of thyroid nodule Hot nodule Hyper-functioning nodule producing thyrotoxicosis Likelihood of malignancy < 1% Cold nodule Benign 80% - Cyst, adenoma, hemorrhage, abscess, focal thyroiditis Likelihood of malignancy 20%

25 II. Evaluate function of thyroid nodule Indeterminate nodule Palpable detected nodule with equal radiotracer uptake to surrounding tissue May be a cold nodule arising from posterior aspect with superimposed normal glandular activity Likelihood of malignancy : Same as cold nodule ( 20%)

26 III. Localize ectopic thyroid tissue Location Anywhere along the line of descent Most common site : Base of tongue Lingual and sublingual thyroid

27 IV. Evaluate cause of congenital hypothyroidism Causes of congenital hypothyroidism Iodine deficiency - most common Agenesis or hypoplasia of thyroid gland Ectopic thyroid Dyshormonogenesis (Organification defect) Agenesis of thyroid gland

28 IV. Evaluate cause of congenital hypothyroidism Dyshormonogenesis Increased uptake at normal position Ectopic thyroid Normal uptake, abnormal position

29 V. Evaluate substernal goiter Sub-sternal goiter Use radioactive iodine Limitation of 99m Tc-pertechnetate Attenuate by sternum & soft tissue Blood pool activity

30 VI. Evaluate post-op. residual thyroid Residual thyroid tissue

31 2. Thyroid uptake study Indications To determine cause of thyrotoxicosis To calculate therapeutic dose of 131 I To evaluate post-op. residual thyroid tissue

32 Thyroid uptake study Preparation : Discontinues interfering agents Factors Thyroid hormone - LT3 - LT4 Excess iodine - KI, cough med., iodinated skin ointment - Iodinated drug Radiographic contrast PTU MMI Duration of effect 2 wk. 4 wk. 2-4 wk. wk. to months. 4 wk. 3-5 days 5-7 days

33 Thyroid uptake study Procedure Oral administration of radioactive iodine Quantify percentage (%) of thyroid uptake Measure at 24 hr. (routine)

34 Factor affecting increased uptake Hyperthyroidism : Graves disease, toxic MNG, toxic adenoma, TSH-producing pituitary tumor, trophoblastic tumor Iodine deficiency Enzyme defect Early Hashimoto thyroiditis Rebound effect after withdraw anti-thyroid drug

35 Factor affecting decreased uptake Hypothyroidism Primary (thyroid) or secondary (pituitary) Blocked trapping Iodine overload Blocked organification : Anti-thyroid drugs Parenchymal destruction : Thyroiditis

36 3. Dx-WBS Indications Thyroid cancer To evaluate treatment response To detect metastases Detect struma ovarii

37 Patient preparation Low iodine intake Thyroid hormone withdrawal Procedures 131 I 2-5 mci 123 I 1-3 mci Oral administration Scan at 2-7 days 3. Dx-WBS

38 3. Dx-WBS Normal Dx-WBS DTC S/P total thyroidectomy and RAIT Physiologic activity - Nasopharynx, oropharynx, salivary glands, stomach, intestine and bladder

39 3. Dx-WBS Struma ovarii - Abnormal uptake in pelvis due to ectopic thyroid tissue in ovary, intense uptake in thyroid SPECT/CT pelvis Dx-WBS

40 Take a break

41 RADIONUCLIDE THERAPY Outline Principle of radionuclide therapy Applications of 131 I treatment Hyperthyroidism Thyroid cancer

42 Radionuclides therapy Administration of radioactive agents that will be trapped in the target organ or tissue for therapeutic purpose. Internal radiotherapy Local irradiation Relatively less toxicity to adjacent tissue or organ

43 131 I treatment Beta rays : Treatment Gamma rays : Imaging 131 I; radioactive iodine enter the thyroid hormone synthesis pathway same as 127 I; stable iodine.

44 131 I treatment in hyperthyroidism Overactive thyroid gland Presented with symptoms of excessive thyroid hormone Thyrotoxicosis

45 Graves disease Diagnosed by symptoms Exophthalmos Confirmed by laboratory testing T3, T4, TSH TSH receptor antibody - Not necessary Normal gland Pretibial myxedema Diffused goiter

46 Toxic nodular goiter Presentation Thyrotoxicosis Obstructive symptoms Asymptomatic, esp. with small nodules : size < cm. Diagnosis Toxic adenoma Toxic MNG Slightly high or normal T3 and T4 Slightly suppressed TSH

47 Treatment of hyperthyroidism Options Medical treatment Surgical treatment Radioactive iodine treatment

48 Medical treatment Control of hyperthyroidism : Anti-thyroid drug Thionamides Methimazole - MMI and Propylthiouracil - PTU Action : Inhibit peroxidase PTU also inhibit peripheral conversion Always consider as 1 st treatment for hyperthyroidism

49 Medical treatment Control of hyperthyroidism : Anti-thyroid drug Advantage Rapid improvement in 2-4 wks. Disadvantage Adverse reaction - Rash, fever, GI symptoms, hepatitis, arthritis, agranulocytosis High rate of relapse ( 50% remission)

50 Medical treatment Control of symptoms : Beta-blockers Action : Inhibit adrenergic effects and peripheral conversion Treatment of choice for thyroiditis Use with caution in older patient, pre-existing COPD, asthma, heart disease

51 Surgical treatment Treatment of choice Pregnancy (2 nd trimester) Large goiters with compressive symptoms Possible co-existing thyroid cancer

52 Surgical treatment Advantage Low rate of relapse Disadvantage High rate of hypothyroidism Risk of hypoparathyroidism Laryngeal nerve injury Requires euthyroidism before surgery

53 Radioactive iodine treatment Treatment of choice Failed medication (unable to titrate down ATD or unable to control hyperthyroidism) Relapse after receiving medical or surgical treatment Major adverse reactions from anti-thyroid drug Life-threatening conditions requiring euthyroid in short period (AF, CHF, cardiomyopathy, periodic paralysis)

54 Radioactive iodine treatment Advantage Low rate of relapse Disadvantage o o Delayed control of symptoms High rate of hypothyroidism Contraindication Pregnancy, breast feeding, young children

55 Radioactive iodine treatment Patient preparation To reduce iodine pool - Low-iodine diet for 1 wk. Time of withdrawal Anti-thyroid drug Expectorants, Lugol s solution Contrast media Amiodarone PTU 3-5 day, MMI 5-7 day 1-3 wk. 1 mo. 3-6 mo.

56 Radioactive iodine treatment Prescribed dose Based on thyroid volume and uptake Dose of 131 I = Gland size (gram) x Standard dose x 100 % 24 hr. 131 I Uptake x 1000 Standard dose : uci/gram vary on severity of disease

57 Radioactive iodine treatment Side effects Transient radiation sickness Transient exacerbation of hyperthyroid in first month Follow-up Re-start ATD in 5-7 days to control thyrotoxicosis Re-evaluate symptoms and titrate down ATD by monitoring TFT in 1-2 month intervals Evaluate treatment outcome at 6 month

58 Radioactive iodine treatment Outcome of 131 I treatment High cure rate with single treatment Euthyroid - Most desirable outcome, small group Hypothyroid - Acceptable outcome, large group ** Always advice this potential outcome ** Subclinical or persistent hyperthyroidism or unable to withdraw/taper down ATD at 6 month post-treatment Re-evaluate with 24 hr. 131 I uptake ± retreat 2 nd dose

59 131 I treatment in thyroid cancer 4 major pathological types of thyroid cancer Papillary Follicular Anaplastic Medullary Differentiated thyroid cancer (DTC) 131 I treatment Incidence Papillary : 60-70% Follicular : 15-20%

60 Treatment of differentiated thyroid cancer 1. Surgery 2. Staging and risk stratification I-treatment 4. Follow-up and therapeutic response evaluation Reference: ATA guideline 2015

61 1. Surgery Thyroidectomy : 1 st treatment Adequate surgery for cancer = Total thyroidectomy If previously done lobectomy, Completion thyroidectomy must be performed.

62 1. Surgery Cervical LN dissection : Optional Clinically involved CLN in central or lateral compartment Prophylactic dissection in advanced PTC

63 2. Staging and risk stratification Post-operative staging Based on ptnm parameters and age Predict disease mortality Risk of recurrence stratification Use for follow-up Both staging and risk of recurrence are used to determine 131 I treatment.

64 Staging T - Tumor size & extension N Lymph node metastasis M Distant metastasis

65 AGE < 45 Stage I or II depends on presence of metastasis Staging

66 Risk of recurrence stratification

67 Risk of recurrence stratification ATA low risk - Intra-thyroidal DTC PTC - LN micro-metastasis, no aggressive histology FTC - Minimal vascular invasion (< 4 foci)

68 Risk of recurrence stratification ATA intermediate risk - Microscopic ETE, CLN metastases PTC with vascular invasion Aggressive histology

69 Risk of recurrence stratification ATA high risk - Distant metastasis Macroscopic ETE Incomplete tumor resection Pathologic LN Ø > 3 cm. Widely invasive FTC

70 Purpose of 131 I treatment Ablation Adjuvant therapy 1. Remnant ablation Treatment To destroy post-op. residual thyroid tissue For intra-thyroidal DTC with complete resection Facilitate follow up

71 Purpose of 131 I treatment 2. Adjuvant therapy To destroy suspected but unproven residual disease For microscopic ETE, vascular invasion, LN metastasis 3. Treatment To treat known or persistent disease For incomplete tumor resection, distant metastasis

72 Indication and benefit of 131 I Intra-thyroidal DTC, size < 1cm. No indication of 131 I ablation

73 Tumor > 1 cm. Considered 131 I treatment based on adverse features e.g. aggressive histology, vascular invasion, advanced age

74 Microscopic ETE, LN metastasis Generally favored 131 I treatment

75 Macroscopic ETE, distant metastasis 131 I treatment is indicated Benefits - Improve disease specific survival and disease free survival

76 I-treatment Pre 131 I-treatment evaluation To evaluate residual thyroid tissue 24 hr. 131 I uptake, thyroid scan, ultrasound Significant amount of residual tissue Re-surgery To evaluate functioning metastasis Dx-WBS, CT scan If present, it may lead to increase 131 I-treatment dosage

77 I treatment Patient preparation Rule out pregnancy and breast feeding Advise birth control Review isolation requirement Discontinue iodine supplements or containing agents

78 I treatment Patient preparation Withdraw thyroid hormone to elevate serum TSH Stimulate iodine trapping in thyroid remnant and functioning metastasis Can use exogenous TSH (rh-tsh) instead of thyroid hormone withdrawal

79 I treatment mci Remnant ablation 100 mci Adjuvant therapy (up to 150 mci) Structural disease (up to 200 mci)

80 I treatment Hospital stays Low-dose (< 30 mci) : Not require High dose Stay in hospital until radiation level is sufficiently low. (about 2-3 days in general) Isolation room

81 I treatment Early side effects Radiation thyroiditis Dysphagia Radiation sialadinitis GI discomfort Nausea Reduced taste Pain at metastatic sites Late side effects Xerostomia BM suppression Pulmonary fibrosis Transient amenorrhea or oligomenorrhea Infertility Second malignancy

82 I treatment Post-therapeutic total body scan Obtain at 2-7 days after treatment dose Baseline imaging Not an imaging to evaluate treatment response

83 4. Follow-up and therapeutic response evaluation Follow-up Initial follow-up Initial TSH suppression Therapeutic response evaluation Long-term follow-up Long-term TSH suppression Disease surveillance

84 Thyroid hormone suppression Rationale Differentiated thyroid cancer express TSH receptor on cell membrane. Suppress TSH with supra-physiologic thyroid hormone to decrease risk of recurrence

85 Initial TSH suppression Initial dosage - Thyroxine 2 µg/kg/day TSH level - Depends on risk of recurrence Risk of recurrence TSH level (mu/l) Low Suppressed Tg < 0.2 ng/ml Suppressed Tg 0.2 ng/ml Intermediate High < 0.1

86 Therapeutic response evaluation Criteria Perform at 6-12 months post 131 I treatment Clinical - Physical examination Biochemical - Lab Tg, TgAb Suppressed Tg - Low TSH, on thyroxine Stimulated Tg - High TSH, off thyroxine Imaging - Dx-WBS, US and others

87 Therapeutic response evaluation 4 categories of response Excellence response Biochemical incomplete response Indeterminate response Structural incomplete response Guide for further management and intensity of follow-up

88 Excellence response Disease free status or NED Def. - Negative clinical, imaging & lab Mx. - Decrease intensity of F/U

89 Biochemical incomplete response Def. - Negative clinical & imaging, positive lab Mx - Serial F/U

90 Indeterminate response Def. - Negative clinical, non-specific imaging or lab Mx - Serial F/U

91 Structural incomplete response Def. - Positive clinical or imaging Mx Additional Tx

92 Long-term TSH suppression TSH level depends on Risk of recurrence Therapeutic response Risk of TSH suppression e.g. age > 60 yr., osteopenia, osteoporosis, tachycardia, AF

93 Long-term TSH suppression Suppression TSH level (mu/l) Indication No All NED exc. high risk of recurrence keep TSH in first 5 years Mild Most of indeterminate & biochemical incomplete response* Moderate to complete < 0.1 Most of structural incomplete response* * Less suppression in patients with higher risk of TSH suppression

94 Long-term TSH suppression

95 Disease surveillance Physical examination Serial Tg, TgAb Imaging - Dx-WBS, US, others imaging as indicated Intensity depends on Risk of recurrence Disease status NED or non-ned

96 KEYS

97 Thyroid function test In vitro Most sensitive - TSH Tumor marker for DTC Tg, interfered by TgAb In vivo Thyroid uptake Conditions affecting uptake - Increased VS decreased Preparation - Withdraw ATD & thyroid hormone

98 Thyroid function test In vivo (cont.) Thyroid scan Radiotracer : 99m Tc-pertechnetate VS RAI Findings - Graves disease, toxic MNG, toxic adenoma, thyroiditis Function of thyroid nodule - Risk of malignancy

99 Treatment of hyperthyroidism Advantages VS disadvantages Medication - Rapid improve VS side effects, high rate of relapse Surgery - Low rate of relapse VS risk of surgery 131 I - Low rate of relapse VS hypothyroidism, contraindication

100 Treatment of hyperthyroidism Candidate Medication - 1 st treatment Surgery - Suspected CA, compressive symptoms 131 I - Failed medication, relapse, require euthyroid in short period, major adverse reactions from ATD

101 Treatment of DTC Surgery - Total or complete thyroidectomy Staging and risk stratification Staging - Predict disease mortality Risk of recurrence - Follow-up Determine 131 I treatment

102 Treatment of DTC Benefit of 131 I - Disease spec. survival & free survival No benefits in intra-thyroidal tumor < 1 cm. Indicated in gross ETE and distant metastases Common side effect of 131 I Early - Acute radiation sickness, thyroiditis, sialadenitis Delayed - Xerostomia

103 Treatment of DTC Initial F/U TSH suppression level - Depends on risk of recurrence Therapeutic response at 6-12 mo. post-rai treatment 4 categories Excellence - Disease free status Structural incomplete - Further treatment

104 Treatment of DTC Long-term F/U TSH suppression level - Depends on risk of recurrence, therapeutic response and risk of TSH suppression Intensity of F/U - Depends on risk of recurrence and disease status

105 Take a break

106 CASE DEMONSTRATION

107 CASE I A 45-year-old woman CC : Palpitation and sweating for 2 weeks PE : Normal size thyroid, generalized mild tenderness Fine tremor of both hands PR 100/min, regular Treatment : Beta-blockers

108 CASE I This patient Normal T FT TSH QUESTION 1 - What is the investigation of choice to evaluate cause of thyrotoxicosis? A. Thyroid scan B. Thyroid uptake C. Either

109 CASE I - Pearls

110 CASE II A 60-year-old woman with relapse Graves disease PE : Diffuse goiter 40 gm. PR 80/min, regular Treatment : MMI (5) 2 x 1 Propanolol (10) 1 x 2 This patient Normal T FT TSH

111 CASE II 24-hour 131 I uptake performed to calculate dose of 131 I treatment = 24% (normal 15-45%) QUESTION 2 - What are the possible causes of normal thyroid uptake in hyperthyroidism patient?

112 CASE II

113 CASE II S/P 131 I treatment 10 mci (uptake 60%, thyroid 40 gm.) Re-start MMI (5) 2 x 1 in 7 days after 131 I treatment F/U at 1 month after RAI treatment On MMI (5) 2 x 1 Clinical mild hyperthyroidism

114 CASE II Pre- RAIT 1 mo. Normal T FT TSH QUESTION 3 - What is the most appropriate management? A. Advice, continue MMI (5) 2 x 1 B. Increases dose of ATD - MMI (5) 3 x 1 C. 2 nd RAI treatment

115 CASE II F/U at 2 months after RAI treatment Clinical - Euthyroidism

116 CASE II 1 mo. 2 mo. Normal T FT TSH QUESTION 4 - What is the most appropriate management? A. Continue MMI (5) 2 x 1 B. Reduce dose of ATD - MMI (5) 1 x 1

117 CASE II F/U at 4 months after RAI treatment.. Clinical - Euthyroid

118 CASE II 2 mo. 4 mo. Normal T FT TSH QUESTION 5 - What is the most appropriate management? A. Reduce dose of MMI (5) to ½ x 1 B. Off MMI C. Off MMI and start thyroxine

119 CASE II F/U at 6 months after RAI treatment.. Clinical - Hypothyroidism

120 CASE II 4 mo. 6 mo. Normal T FT TSH QUESTION 6 - What is the most appropriate management?

121 CASE II - Pearls

122 CASE III A 35-year-old woman CC : Right thyroid nodule with palpitation and sweating for 6 months PE : Palpable right thyroid nodule, size 3 cm. PR 90/min, regular

123 CASE III This patient Normal T FT TSH QUESTION 7 - What is the investigation of choice to evaluate function of thyroid nodule? A. Thyroid scan B. Thyroid uptake C. Either

124 CASE III - Pearls

125 CASE IV A 22-year-old woman, underlying hyperthyroidism CC : Progressive enlargement of a left thyroid nodule PE : Diffuse goiter with a palpable left thyroid nodule Exophthalmos both eyes PR 88/min, regular Treatment : MMI (5) 1x1

126 CASE IV This patient Normal T FT TSH QUESTION 8 - What is the investigation of choice to evaluate function of thyroid nodule? A. Thyroid scan B. Thyroid uptake C. Either

127 CASE IV What to do next?

128 CASE IV QUESTION 9 - What is the treatment of choice for this patient? A. Anti-thyroid drug B. Surgery Total thyroidectomy C. Radioactive iodine

129 CASE IV - Pearls

130 CASE V A 37-year-old woman CC : Palpitation, sweating, weight loss 5kg. in 3 mo. PE : Slightly enlarged thyroid gland Fine tremor of both hands No exophthalmos PR 98/min, irregular

131 CASE V This patient Normal T FT TSH < QUESTION 10 - What is the treatment of choice for this patient? A. Anti-thyroid drug B. Surgery C. Radioactive iodine

132 CASE V Treatment :.. 2 months after receiving treatment, presented with MP rash Work-up : CBC, LFT, UA - normal This patient Normal T FT TSH

133 CASE V QUESTION 11 - What is the most appropriate treatment for this patient? A. Change anti-thyroid drug B. Surgery C. Radioactive iodine

134 CASE V Treatment :.. Persistent hyperthyroidism after 2 years of treatment This patient Normal T FT TSH

135 CASE V QUESTION 12 - What is the most appropriate treatment for this patient? A. Anti-thyroid drug B. Surgery C. Radioactive iodine

136 CASE V - Pearls

137 CASE VI A 24-year-old woman CC : Progressive enlargement of a palpable right thyroid nodule, size 3 cm. for 6 months PE : Clinical euthyroid Right thyroid nodule

138 CASE VI QUESTION 13 - What is the investigation of choice to evaluate thyroid nodule? A. Thyroid scan B. Thyroid uptake C. US-guided FNA

139 CASE VI QUESTION 14 - What is the most appropriate treatment for this patient? A. Radioactive iodine B. Surgery C. Repeat US-guided FNA

140 CASE VI S/P Right lobectomy Pathology : Papillary thyroid cancer, classical variant Size 3.2 x 2.5 x 1.8 cm. Microscopic extra-thyroidal invasion No vascular invasion

141 CASE VI QUESTION 15 - What is the most appropriate treatment for this patient? A. Radioactive iodine B. Completion thyroidectomy C. Long-term follow-up

142 CASE VI.. QUESTION 16 - Stage Due to QUESTION 17 - Risk of recurrence Due to

143 CASE VI QUESTION 18 - What is an objective of 131 I treatment for this patient? A. Remnant ablation - To facilitate follow-up B. Adjuvant therapy - To destroy suspected but unproven residual disease

144 CASE VI Post-Tx WBS 131 I treatment 150 mci Hospital stay 3 days This patient Normal T TSH > Anterior neck Stim. Tg < TgAb 17.3 < 40

145 CASE VI Start thyroxine 2 µg/kg/day Initial F/U at 2 month after 131 I treatment QUESTION 19 - Initial TSH suppression level depends on This patient Normal T TSH

146 CASE VI At 6 month after 131 I treatment This patient Normal T TSH Supp. Tg < TgAb < 10 < 40

147 CASE VI Dx-WBS At 8 month after treatment US thyroid - Negative This patient Normal T TSH > Stim. Tg < TgAb < 10 < 40 Anterior neck

148 CASE VI Therapeutic response.. Risk of recurrence.. Risk of TSH suppression..

149 CASE VI This patient Normal T TSH QUESTION 20 - What is the appropriate long-term TSH suppression level for this patient? A. Moderate to complete suppression, TSH < 0.1 B. Mild suppression, TSH C. No suppression, TSH

150 CASE VI - Pearls

151 CASE VII A 58-year-old woman CC : Progressive enlargement of right thyroid nodule for 6 months PE : Nodular enlargement of right thyroid gland Palpable right cervical LNs

152 CASE VII Neck CT scan Mass at right thyroid lobe Right cervical LN

153 CASE VII S/P Total thyroidectomy with right CLN dissection Pathology : Papillary thyroid cancer, Ø 4.0 x 3.2 x 2.8 cm. Presence of angiolymphatic invasion Presence of perithyroidal soft tissue invasion Right cervical LNs level II-IV - Metastatic LN 15/21, maximum Ø 2.5 cm.

154 CASE VII Base on pathological report Stage. Risk of recurrence. Due to

155 CASE VII Post-Tx WBS Admitted for 131 I treatment 150 mci Hospital stay 3 days This patient Normal T TSH > Stim. Tg TgAb < 10 < 40 Anterior neck

156 CASE VII Lung metastasis on post-tx WBS Change stage to stage Change risk of recurrence to SPECT SPECT/CT

157 CASE VII Initial F/U at 2 month after treatment QUESTION 21 - What is the appropriate initial TSH suppression level for this patient? A. < 0.1 (high) B (intermediate) This patient Normal C (low) T TSH

158 CASE VII At 6 month after treatment This patient Normal T TSH Supp. Tg TgAb < 10 < 40

159 CASE VII Dx-WBS At 8 month after treatment This patient Normal Anterior neck T TSH Stim.Tg TgAb < 10 < 40

160 CASE VII Therapeutic response.. Risk of recurrence.. Risk of TSH suppression..

161 CASE VII QUESTION 22 - What is the most appropriate management for this patient? A. Moderate to complete TSH suppression, TSH < 0.1 B. Admit for 2 nd 150 mci 131 I treatment C. Both

162 CASE VII - Pearls

163 CASE VIII A 35-year-old woman CC : Incidentally found right thyroid nodule from annual check-up PE : A palpable 1 cm. right thyroid nodule No palpable cervical LNs

164 CASE VIII US-guided FNA : Suspicious of papillary thyroid CA S/P Total thyroidectomy Pathology : Papillary thyroid cancer, classical variant Right lobe Ø 1.2 cm. Absence of angiolymphatic invasion Absence of perithyroidal soft tissue invasion

165 CASE VIII Base on pathological report Stage. Risk of recurrence.

166 CASE VIII QUESTION 23 - What is an objective of 131 I treatment for this patient? A. Remnant ablation - To facilitate follow-up B. Adjuvant therapy - To destroy suspected but unproven residual disease

167 CASE VIII Post-Tx WBS 131 I ablation 30 mci OPD case This patient Normal T TSH Stim. Tg TgAb 53.4 < 40 Anterior neck

168 CASE VIII After RAI treatment 2 month - TSH month This patient Normal T TSH Supp. Tg < TgAb < 10 < 40

169 CASE VIII Dx-WBS At 8 month after treatment US thyroid - negative This patient Normal T TSH Stim.Tg < TgAb < 10 < 40 Anterior neck

170 CASE VIII QUESTION 24 - What is the therapeutic response (among 4 categories) of this patient? A. Excellence response B. Biochemical incomplete response C. Indeterminate response D. Structural incomplete response

171 CASE VIII - Pearls

172 Thank you for your attention

Imaging in Pediatric Thyroid disorders: US and Radionuclide imaging. Deepa R Biyyam, MD Attending Pediatric Radiologist

Imaging in Pediatric Thyroid disorders: US and Radionuclide imaging. Deepa R Biyyam, MD Attending Pediatric Radiologist Imaging in Pediatric Thyroid disorders: US and Radionuclide imaging Deepa R Biyyam, MD Attending Pediatric Radiologist Imaging in Pediatric Thyroid disorders: Imaging modalities Outline ACR-SNM-SPR guidelines

More information

Adjuvant therapy for thyroid cancer

Adjuvant therapy for thyroid cancer Carcinoma of the thyroid Adjuvant therapy for thyroid cancer John Hay Department of Radiation Oncology Vancouver Cancer Centre Department of Surgery UBC 1% of all new malignancies 0.5% in men 1.5% in women

More information

42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50%

42 yr old male with h/o Graves disease and prior I 131 treatment presents with hyperthyroidism and undetectable TSH. 2 hr uptake 20%, 24 hr uptake 50% Pinhole images of the neck are acquired in multiple projections, 24hrs after the oral administration of approximately 200 µci of I123. Usually, 24hr uptake value if also calculated (normal 24 hr uptake

More information

Iodine 131 thyroid Therapy. Sara G. Johnson, MBA, CNMT, NCT President SNMMI-TS VA Healthcare System San Diego

Iodine 131 thyroid Therapy. Sara G. Johnson, MBA, CNMT, NCT President SNMMI-TS VA Healthcare System San Diego Iodine 131 thyroid Therapy Sara G. Johnson, MBA, CNMT, NCT President SNMMI-TS VA Healthcare System San Diego OBJECTIVES Describe the basics of thyroid gland anatomy and physiology Outline the disease process

More information

2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines

2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines 2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines Angela M. Leung, MD, MSc, ECNU November 5, 2016 Outline Workup of nontoxic thyroid nodule(s) Ultrasound FNAB Management of FNAB results

More information

OUTLINE. Regulation of Thyroid Hormone Production Common Tests to Evaluate the Thyroid Hyperthyroidism - Graves disease, toxic nodules, thyroiditis

OUTLINE. Regulation of Thyroid Hormone Production Common Tests to Evaluate the Thyroid Hyperthyroidism - Graves disease, toxic nodules, thyroiditis THYROID DISEASE OUTLINE Regulation of Thyroid Hormone Production Common Tests to Evaluate the Thyroid Hyperthyroidism - Graves disease, toxic nodules, thyroiditis OUTLINE Hypothyroidism - Hashimoto s thyroiditis,

More information

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose.

Thyroid Nodule. Disclosure. Learning Objectives P A P A P A 3/18/2014. Nothing to disclose. Thyroid Nodule Evaluating the patient with a thyroid nodule and some management options. Miguel V. Valdez PA C Disclosure Nothing to disclose. Learning Objectives Examination of thyroid gland Options for

More information

Hyperthyroidism Diagnosis and Treatment. April Janet A. Schlechte, M.D.

Hyperthyroidism Diagnosis and Treatment. April Janet A. Schlechte, M.D. Hyperthyroidism Diagnosis and Treatment Family Practice Refresher Course April 2015 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any

More information

Evaluation and Management of Thyroid Nodules. Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada

Evaluation and Management of Thyroid Nodules. Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada Evaluation and Management of Thyroid Nodules Nick Vernetti, MD, FACE Palm Medical Group Las Vegas, Nevada Disclosure Consulting Amgen Speaking Amgen Objectives Understand the significance of incidental

More information

Differentiated Thyroid Cancer: Initial Management

Differentiated Thyroid Cancer: Initial Management Page 1 ATA HOME GIVE ONLINE ABOUT THE ATA JOIN THE ATA MEMBER SIGN-IN INFORMATION FOR PATIENTS FIND A THYROID SPECIALIST Home Management Guidelines for Patients with Thyroid Nodules and Differentiated

More information

Women s Health in General Practice Symposium 2015 Thyroid & Parathyroid Cases

Women s Health in General Practice Symposium 2015 Thyroid & Parathyroid Cases Women s Health in General Practice Symposium 2015 Thyroid & Parathyroid Cases Bill Fleming Epworth Freemasons Hospital 1 Common Endocrine Presentations anatomical problems thyroid nodule / goitre embryological

More information

AN INTRODUCTION TO NUCLEAR MEDICINE

AN INTRODUCTION TO NUCLEAR MEDICINE AN INTRODUCTION TO NUCLEAR MEDICINE WITH RESPECT TO THYROID DISORDERS By: B.Shafiei MD Nuclear Physician Taleghani Medical Center Radioactive: An element with Unstable Nucleus (Excess Energy), can achieve

More information

Hyperthyroidism. Objectives. Clinical Manifestations. Slide 1. Slide 2. Slide 3. Implications for Primary Care. hyperthyroidism

Hyperthyroidism. Objectives. Clinical Manifestations. Slide 1. Slide 2. Slide 3. Implications for Primary Care. hyperthyroidism 1 Hyperthyroidism Implications for Primary Care Laura A. Ruby, DNP, CRNP Wellspan Endocrinology 2 Objectives! Discuss the clinical manifestations of hyperthyroidism! Review the use of the diagnostic studies!

More information

THYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine

THYROID CANCER IN CHILDREN. Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine THYROID CANCER IN CHILDREN Humberto Lugo-Vicente MD FACS FAAP Professor Pediatric Surgery UPR School of Medicine Thyroid nodules Rare Female predominance 4-fold as likely to be malignant Hx Radiation exposure?

More information

Approach to Thyroid Nodules

Approach to Thyroid Nodules Approach to Thyroid Nodules Alice Y.Y. Cheng, MD, FRCPC Twitter: @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted

More information

DISORDERS OF THE THYROID GLAND SIGNS, SYMPTOMS, & TREATMENT ENDOCRINE SYSTEM AT A GLANCE OBJECTIVES ANATOMY OF THE THYROID

DISORDERS OF THE THYROID GLAND SIGNS, SYMPTOMS, & TREATMENT ENDOCRINE SYSTEM AT A GLANCE OBJECTIVES ANATOMY OF THE THYROID OBJECTIVES DISORDERS OF THE THYROID GLAND SIGNS, SYMPTOMS, & TREATMENT Stephanie Blackburn, MHS, MLS(ASCP) CM LSU Health Shreveport Clinical Laboratory Science Program Discuss the synthesis and action

More information

Approach to thyroid dysfunction

Approach to thyroid dysfunction Approach to thyroid dysfunction Alice Y.Y. Cheng, MD, FRCPC Twitter: @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or

More information

Lecture title. Name Family name Country

Lecture title. Name Family name Country Lecture title Name Family name Country Nguyen Thy Khue, MD, PhD Department of Endocrinology HCMC University of Medicine and Pharmacy, MEDIC Clinic Hochiminh City, Viet Nam Provided no information regarding

More information

Pediatric Thyroid Cancer Lung Metastases. Liora Lazar MD

Pediatric Thyroid Cancer Lung Metastases. Liora Lazar MD Pediatric Thyroid Cancer Lung Metastases Liora Lazar MD Differentiated thyroid cancer (DTC) The 3rd most common solid tumor in childhood and adolescence Accounting for 1.5%-3% of all childhood cancers

More information

Toxic MNG Thyroiditis 5-15

Toxic MNG Thyroiditis 5-15 Hyperthyroidism Facts Prevalence 0.5-1.0%, more common in women Thyrotoxicosis is excess thyroid hormones from endogenous or exogenous sources Hyperthyroidism is excess thyroid hormones from thyroid gland

More information

Index. radiologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. radiologic.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A ACC. See Adrenal cortical carcinoma. Acromegaly and the pituitary gland, 551 Acute suppurative thyroiditis, 405, 406 Addison, Thomas and

More information

Update In Hyperthyroidism

Update In Hyperthyroidism Update In Hyperthyroidism CME Away India & Sri Lanka March 23 - April 7, 2018 Richard A. Bebb MD, ABIM, FRCPC Consultant Endocrinologist Medical Subspecialty Institute Cleveland Clinic Abu Dhabi Copyright

More information

Thyroid and Antithyroid Drugs. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine April 2014

Thyroid and Antithyroid Drugs. Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine April 2014 Thyroid and Antithyroid Drugs Munir Gharaibeh, MD, PhD, MHPE Faculty of Medicine April 2014 Anatomy and histology of the thyroid gland Located in neck adjacent to the 5 th cervical vertebra (C5). Composed

More information

How good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status

How good are we at finding nodules? Thyroid Nodules Thyroid Cancer Epidemiology Initial management Long-term follow up Disease-free status New Perspectives in Thyroid Cancer Jennifer Sipos, MD Assistant Professor of Medicine Division of Endocrinology The Ohio State University Outline Thyroid Nodules Thyroid Cancer Epidemiology Initial management

More information

A rare case of solitary toxic nodule in a 3yr old female child a case report

A rare case of solitary toxic nodule in a 3yr old female child a case report Volume 3 Issue 1 2013 ISSN: 2250-0359 A rare case of solitary toxic nodule in a 3yr old female child a case report *Chandrasekaran Maharajan * Poongkodi Karunakaran *Madras Medical College ABSTRACT A three

More information

4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.

4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey. Management of Differentiated Thyroid Cancer: Head Neck Surgeon Perspective Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey Thyroid gland Small endocrine gland:

More information

Austin Radiological Association Nuclear Medicine Procedure THERAPY FOR THYROID CANCER (I-131 as Sodium Iodide)

Austin Radiological Association Nuclear Medicine Procedure THERAPY FOR THYROID CANCER (I-131 as Sodium Iodide) Austin Radiological Association Nuclear Medicine Procedure THERAPY FOR THYROID CANCER (I-131 as Sodium Iodide) Overview Indications I-131 therapy for Thyroid Cancer, of the papillo-follicular type, is

More information

B-Resistance to the action of hormones, Hormone resistance characterized by receptor mediated, postreceptor.

B-Resistance to the action of hormones, Hormone resistance characterized by receptor mediated, postreceptor. Disorders of the endocrine system 38 Disorders of endocrine system mainly are caused by: A-Deficiency or an excess of a single hormone or several hormones: - deficiency :can be congenital or acquired.

More information

Disclosures. Learning objectives. Case 1A. Autoimmune Thyroid Disease: Medical and Surgical Issues. I have nothing to disclose.

Disclosures. Learning objectives. Case 1A. Autoimmune Thyroid Disease: Medical and Surgical Issues. I have nothing to disclose. Disclosures Autoimmune Thyroid Disease: Medical and Surgical Issues I have nothing to disclose. Chrysoula Dosiou, MD, MS Clinical Assistant Professor Division of Endocrinology Stanford University School

More information

- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer

- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer Thyroid Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: 1. Lenvina is the first line therapy with powerful durable response and superior PFS in pts with RAI-refractory disease.

More information

Thyrotoxicosis in Pregnancy: Diagnose and Management

Thyrotoxicosis in Pregnancy: Diagnose and Management Thyrotoxicosis in Pregnancy: Diagnose and Management Yuanita Asri Langi email: meralday@yahoo.co.id Endocrinology & Metabolic Division, Internal Medicine Department, Prof.dr.R.D. Kandou Hospital/ Sam Ratulangi

More information

131-I Therapy Planning in Thyroid Cancer: The role of diagnostic radioiodine scans

131-I Therapy Planning in Thyroid Cancer: The role of diagnostic radioiodine scans 131-I Therapy Planning in Thyroid Cancer: The role of diagnostic radioiodine scans Anca M. Avram, M.D. Associate Professor of Radiology Department of Nuclear Medicine University of Michigan Ann Arbor,

More information

Diseases of thyroid & parathyroid glands (1 of 2)

Diseases of thyroid & parathyroid glands (1 of 2) Diseases of thyroid & parathyroid glands (1 of 2) Thyroid diseases Thyrotoxicosis Hypothyroidism Thyroiditis Graves disease Goiters Neoplasms Chronic Lymphocytic (Hashimoto) Thyroiditis Subacute Granulomatous

More information

Thyroid nodules. Most thyroid nodules are benign

Thyroid nodules. Most thyroid nodules are benign Thyroid nodules Postgraduate Course in General Surgery Jessica E. Gosnell MD Assistant Professor March 22, 2011 Most thyroid nodules are benign thyroid nodules occur in 77% of the world s population palpable

More information

THYROID DISEASE IN CHILDREN

THYROID DISEASE IN CHILDREN THYROID DISEASE IN CHILDREN Michelle Schweiger, D.O. Center for Pediatric and Adolescent Endocrinology Cleveland Clinic Foundation Neither I nor any immediate family members have any financial interests

More information

Risk Adapted Follow-Up

Risk Adapted Follow-Up Risk Adapted Follow-Up Individualizing Follow- Up Strategies R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Medical College

More information

I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER

I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Advances in Medical and Surgical Management of Thyroid Cancer January 23-24, 2015 I-131 ABLATION AND ADJUVANT THERAPY OF THYROID CANCER 2015 Leonard Wartofsky,

More information

John Sutton, DO, FACOI, FACE, CCD. Carson Tahoe Endocrinology Carson City, NV KCOM Class of 1989

John Sutton, DO, FACOI, FACE, CCD. Carson Tahoe Endocrinology Carson City, NV KCOM Class of 1989 John Sutton, DO, FACOI, FACE, CCD Carson Tahoe Endocrinology Carson City, NV KCOM Class of 1989 No Disclosures Disease Of the Thyroid Iodide Metabolism/Synthesis of Thyroid Hormone Trap Oxidation Organification(catalyzed

More information

LABORATORY TESTS FOR EVALUATION OF THYROID DISORDERS

LABORATORY TESTS FOR EVALUATION OF THYROID DISORDERS LABORATORY TESTS FOR EVALUATION OF THYROID DISORDERS Maryam Tohidi Anatomical & clinical pathologist Research Institute for Endocrine Sciences THYROID GLAND (15-25 gr), (12-20 gr), 2 lobes connected by

More information

Laura Trask, MD FACP Central Maine Endocrinology Lewiston, ME

Laura Trask, MD FACP Central Maine Endocrinology Lewiston, ME Laura Trask, MD FACP Central Maine Endocrinology Lewiston, ME 795-7520 traskla@cmhc.org No disclosures Objectives To have an understanding of hyperthyroidism To have an understanding of the management

More information

Nuclear Medicine Head and Neck Region. Bán Zsuzsanna, MD University of Pécs, Department of Nuclear Medicine

Nuclear Medicine Head and Neck Region. Bán Zsuzsanna, MD University of Pécs, Department of Nuclear Medicine Nuclear Medicine Head and Neck Region Bán Zsuzsanna, MD University of Pécs, Department of Nuclear Medicine Thyroid scintigraphy Parathyroid scintigraphy F18-FDG PET examinations in head and neck cancer

More information

Anca M. Avram, M.D. Professor of Radiology

Anca M. Avram, M.D. Professor of Radiology Thyroid Cancer Theranostics: the case for pre-treatment diagnostic staging 131-I scans for 131-I therapy planning Anca M. Avram, M.D. Professor of Radiology Department of Nuclear Medicine University of

More information

Alvin C. Powers, M.D. 1/27/06

Alvin C. Powers, M.D. 1/27/06 Thyroid Histology Follicular Cells ECF side Apical lumen Thyroid Follicles -200-400 um Parafollicular or C-cells Colloid Photos from University of Manchester and tutorial created by Dr. James Crimando,

More information

1. OVERVIEW AND INDICATIONS

1. OVERVIEW AND INDICATIONS 1. OVERVIEW AND INDICATIONS (adapted from Society of Nuclear Medicine Procedure Guideline for Thyroid Scintigraphy and other sources) a) Evaluation of the general structure of the thyroid gland (e.g. nodular

More information

A Review of Differentiated Thyroid Cancer

A Review of Differentiated Thyroid Cancer A Review of Differentiated Thyroid Cancer April 21 st, 2016 FPON Webcast Jonn Wu BMSc MD FRCPC Radiation Oncologist, Vancouver Centre Chair, Provincial H&N Tumour Group, BCCA Clinical Associate Professor,

More information

Thyroid nodules 3/22/2011. Most thyroid nodules are benign. Thyroid nodules: differential diagnosis

Thyroid nodules 3/22/2011. Most thyroid nodules are benign. Thyroid nodules: differential diagnosis Most thyroid nodules are benign Thyroid nodules Postgraduate Course in General Surgery thyroid nodules occur in 77% of the world s population palpable thyroid nodules occur in about 5% of women and 1%

More information

Management guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007

Management guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007 Management guideline for patients with differentiated thyroid Teeraporn Ratanaanekchai ENT, KKU 17 October 2007 Incidence (Srinagarind Hospital, 2005, both sex) Site (all) cases % 1. Liver 1178 27 2. Lung

More information

Virginia ACP Clinical Update Thyroid Clinical Pearls. University of Virginia. Richard J. Santen MD

Virginia ACP Clinical Update Thyroid Clinical Pearls. University of Virginia. Richard J. Santen MD Virginia ACP Clinical Update Thyroid Clinical Pearls University of Virginia Richard J. Santen MD Goal Provide a guide to frequently encountered problems in thyroid disease Follow my approach to recently

More information

THYROTOXICOSIS DR.J.BALA KUMAR 2 ND YR SURGERY PG

THYROTOXICOSIS DR.J.BALA KUMAR 2 ND YR SURGERY PG THYROTOXICOSIS DR.J.BALA KUMAR 2 ND YR SURGERY PG What is the difference between thyrotoxicosis and hyperthyroidism Thyrotoxicosis Thyrotoxicosis is defined as the state of thyroid hormone excess and is

More information

Thyroid disorders. Dr Enas Abusalim

Thyroid disorders. Dr Enas Abusalim Thyroid disorders Dr Enas Abusalim Thyroid physiology The hypothalamic pituitary thyroid axis And peripheral conversion of T4 to T3, WHERE, AND BY WHAT ENZYME?? Only relatively small concentrations of

More information

2. RADIOPHARMACEUTICALS UTILIZED

2. RADIOPHARMACEUTICALS UTILIZED 1. OVERVIEW AND INDICATIONS (adapted from Society of Nuclear Medicine Procedure Guideline for Thyroid Uptake Measurement, Version 3.0; reprinted from http://snmmi.files.cmsplus.com/docs/thyroid%20uptake%20measure%20v3%200.pdf,

More information

Dynamic Risk Stratification:

Dynamic Risk Stratification: Dynamic Risk Stratification: Using Risk Estimates to Guide Initial Management R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine

More information

PEDIATRIC Ariel Katz MD

PEDIATRIC Ariel Katz MD PEDIATRIC Ariel Katz MD Dept. Otolaryngology Head &Neck Surgery Wolfson Medical Center Holon, Israel OBJECTIVES Overview/Background Epidemiology/Etiology Intro to Guidelines Workup Treatment Follow-Up

More information

Thyroid Gland. Patient Information

Thyroid Gland. Patient Information Thyroid Gland Patient Information Contact details for Endocrine and Thyroid Clinics Hawke s Bay Fallen Soldiers Memorial Hospital Villa 16 Phone: 06 8788109 ext 5891 Text: 0274 102 559 Email: endoclinic@hbdhb.govt.nz

More information

Disorders of the Thyroid Gland

Disorders of the Thyroid Gland Disorders of the Thyroid Gland István Takács MD., PhD, 1st Department of Medicine, Semmelweis University Connection to the dentistry: close to each other higher operation risk radiating pain macroglossia

More information

Hypothalamo-Pituitary-Thyroid Axis

Hypothalamo-Pituitary-Thyroid Axis SMGr up Hypothalamo-Pituitary-Thyroid Axis Orluwene Chituru Godwill 1 * and Ohiri John U 1 1 Chemical Pathology Department, University of Port Harcourt Teaching Hospital, Nigeria *Corresponding author:

More information

5/18/2013. Most thyroid nodules are benign. Thyroid nodules: new techniques in evaluation

5/18/2013. Most thyroid nodules are benign. Thyroid nodules: new techniques in evaluation Most thyroid nodules are benign Thyroid nodules: new techniques in evaluation Incidence Etiology Risk factors Diagnosis Gene classification system Treatment Postgraduate Course in General Surgery Jessica

More information

5/3/2017. Ahn et al N Engl J Med 2014; 371

5/3/2017. Ahn et al N Engl J Med 2014; 371 Alan Failor, M.D. Clinical Professor of Medicine Division of Metabolism, Endocrinology and Nutrition University of Washington April 20, 2017 No disclosures to report 1. Appropriately evaluate s in adult

More information

Persistent & Recurrent Differentiated Thyroid Cancer

Persistent & Recurrent Differentiated Thyroid Cancer Persistent & Recurrent Differentiated Thyroid Cancer Electron Kebebew University of California, San Francisco Department of Surgery Objectives Risk factors for persistent & recurrent disease Causes of

More information

Case 5: Thyroid cancer in 42 yr-old woman with Graves disease

Case 5: Thyroid cancer in 42 yr-old woman with Graves disease Case 5: Thyroid cancer in 42 yr-old woman with Graves disease Giuliano Mariani Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa (Italy) Thyroid cancer in 42 yr-old woman with

More information

Thyroid Plus. Central Thyroid Regulation & Activity. Peripheral Thyroid Function. Thyroid Auto Immunity. Key Guide. Patient: DOB: Sex: F MRN:

Thyroid Plus. Central Thyroid Regulation & Activity. Peripheral Thyroid Function. Thyroid Auto Immunity. Key Guide. Patient: DOB: Sex: F MRN: Thyroid Plus Patient: DOB: Sex: F MRN: Order Number: Completed: Received: Collected: Sample Type - Serum Result Reference Range Units Central Thyroid Regulation & Activity Total Thyroxine (T4) 127 127

More information

Evaluation and Management of Thyroid Nodules. Overview of Thyroid Nodules and Their Management. Thyroid Nodule detection: U/S versus Exam

Evaluation and Management of Thyroid Nodules. Overview of Thyroid Nodules and Their Management. Thyroid Nodule detection: U/S versus Exam Overview of Thyroid Nodules and Their Management Matthew D. Ringel, M.D. Professor of Medicine Divisions of Endocrinology and Oncology, The Ohio State University Co-Director, Thyroid Cancer Unit Arthur

More information

Chapter I.A.1: Thyroid Evaluation Laboratory Testing

Chapter I.A.1: Thyroid Evaluation Laboratory Testing Chapter I.A.1: Thyroid Evaluation Laboratory Testing Jennifer L. Poehls, MD and Rebecca S. Sippel, MD, FACS THYROID FUNCTION TESTS Overview Thyroid-stimulating hormone (TSH) is produced by the anterior

More information

Thyroid Hormones (T 4 & T 3 )

Thyroid Hormones (T 4 & T 3 ) 1 Thyroid Hormones (T 4 & T 3 ) Normalize growth and development, body temperature, and energy levels. Used as thyroid replacement therapy in hypothyroidism. Thyroxine (T 4 ) is peripherally metabolized

More information

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies

More information

Hyperthyroidism, Inflammatory Disorders

Hyperthyroidism, Inflammatory Disorders Hyperthyroidism, Inflammatory Disorders free T4 Howard J. Sachs, MD www.12daysinmarch.com Hyperthyroidism, Inflammatory Disorders The total T4 may be elevated in pregnancy and with OCP use Graves I 123

More information

The Thyroid and Pregnancy OUTLINE OF DISCUSSION 3/19/10. Francis S. Greenspan March 19, Normal Physiology. 2.

The Thyroid and Pregnancy OUTLINE OF DISCUSSION 3/19/10. Francis S. Greenspan March 19, Normal Physiology. 2. The Thyroid and Pregnancy Francis S. Greenspan March 19, 2010 OUTLINE OF DISCUSSION 1. Normal Physiology 2. Hypothyroidism 3. Hyperthyroidism 4. Thyroid Nodules and Cancer NORMAL PHYSIOLOGY Iodine Requirements:

More information

BELIEVE MIDWIFERY SERVICES

BELIEVE MIDWIFERY SERVICES TITLE: THYROID DISEASE IN PREGNANCY EFFECTIVE DATE: July, 2013 POLICY STATEMENT: Pregnancy changes significantly the values influenced by the serum thyroid binding hormone level (i.e., total thyroxine,

More information

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary

Thyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary Thyroid nodules - medical and surgical management JRE Davis NR Parrott Endocrinology and Endocrine Surgery Manchester Royal Infirmary Thyroid nodules - prevalence Thyroid nodules common, increase with

More information

I-123 Thyroid Scintigraphy

I-123 Thyroid Scintigraphy APPROVED BY: Director of Radiology Page 1 of 6 I-123 Thyroid Scintigraphy Primary Indications: Thyroid scintigraphy with I-123 is indicated to evaluate thyroid morphology and global and/or regional function

More information

Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer

Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer Strategies for detection of recurrent disease in longterm follow-up of differentiated thyroid cancer A rational approach to longterm follow-up based on dynamic risk assessment. World Congress on Thyroid

More information

The Number Games and Thyroid Function Arshia Panahloo Consultant Endocrinologist St George s Hospital

The Number Games and Thyroid Function Arshia Panahloo Consultant Endocrinologist St George s Hospital The Number Games and Thyroid Function Arshia Panahloo Consultant Endocrinologist St George s Hospital Presentation Today: Common thyroid problems and treatments Pregnancy related thyroid problems The suppressed

More information

DRUGS. 4- Two molecules of DIT combine within the thyroglobulinto form L-thyroxine (T4)' One molecule of MIT & one molecule of DIT combine to form T3

DRUGS. 4- Two molecules of DIT combine within the thyroglobulinto form L-thyroxine (T4)' One molecule of MIT & one molecule of DIT combine to form T3 THYROID HORMONEs & ANTITHYROID The thyroid secretes 2 types of hormones: DRUGS 1- Iodine containing amino acids (are important for growth, development and metabolism) and these are: triodothyronine, tetraiodothyronine,(

More information

4) Thyroid Gland Defects - Dr. Tara

4) Thyroid Gland Defects - Dr. Tara 4) Thyroid Gland Defects - Dr. Tara Thyroid Pituitary Axis TRH secreted in the hypothalamus stimulates production and Secretion of TSH TSH stimulates secretion of T3, T4 T4 has negative feedback on secretion

More information

Thyroid Disease. I have no disclosures. Overview TSH. Matthew Kim, M.D. July, 2012

Thyroid Disease. I have no disclosures. Overview TSH. Matthew Kim, M.D. July, 2012 Thyroid Disease I have no disclosures Matthew Kim, M.D. July, 2012 Overview Thyroid Function Tests Hyperthyroidism Hypothyroidism Subclinical Thyroid Disease Thyroid Nodules Questions TSH Best single screening

More information

The Thyroid: No mystery. Just need all the pieces to the puzzle.

The Thyroid: No mystery. Just need all the pieces to the puzzle. The Thyroid: No mystery. Just need all the pieces to the puzzle. Todd Chennell, MS, RN ANP-C Endocrine surgery University of Rochester 2018 1 According to the American Thyroid Association, 12 percent of

More information

25/10/56. Hypothyroidism Myxedema in adults Cretinism congenital deficiency of thyroid hormone Hashimoto thyroiditis. Simple goiter (nontoxic goiter)

25/10/56. Hypothyroidism Myxedema in adults Cretinism congenital deficiency of thyroid hormone Hashimoto thyroiditis. Simple goiter (nontoxic goiter) THERAPEUTIC USES OF THYROID HORMONE Supeecha Wittayalertpunya Wannarasmi Ketchart Nov 2013 Hyperthyroidism (Thyrotoxicosis) Grave s disease (diffuse toxic goiter) Toxic uninodular & Toxic multinodular

More information

Update on Gestational Thyroid Disease. Aidan McElduff The Discipline of Medicine, The University of Sydney

Update on Gestational Thyroid Disease. Aidan McElduff The Discipline of Medicine, The University of Sydney IADPSG 2016 Update on Gestational Thyroid Disease Aidan McElduff The Discipline of Medicine, The University of Sydney IADPSG 2016 DISCLOSURES and AIM Nil to disclose Aim: to provide an overview 2017 Guidelines

More information

Oh, I get it, the TSH goes up and down

Oh, I get it, the TSH goes up and down Evaluation and Management of the Thyroid Nodule Oh, I get it, the TSH goes up and down UCSF Head and Neck Conference October 24, 2008 Peter A. Singer, M.D. Professor and Chief Clinical Endocrinology University

More information

Pregnancy & Thyroid. Zohreh Moosavi Associate professor of Endocriology Imam Reza General Hospital Mashad University. Imam Reza weeky Conferance

Pregnancy & Thyroid. Zohreh Moosavi Associate professor of Endocriology Imam Reza General Hospital Mashad University. Imam Reza weeky Conferance Pregnancy & Thyroid Zohreh Moosavi Associate professor of Endocriology Imam Reza General Hospital Mashad University Imam Reza weeky Conferance Objectives Thyroid Disorders & Pregnancy Normal thyroid phsyiology

More information

What you need to know about Thyroid Cancer

What you need to know about Thyroid Cancer What you need to know about Thyroid Cancer This booklet has been designed to help you to learn more about your thyroid cancer. It covers the most important areas and answers some of the frequently asked

More information

Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer

Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Its Not Just About the Nodes AACE Advances in Medical and Surgical Management of Thyroid Cancer - 2017 Robert A. Levine, MD,

More information

Decoding Your Thyroid Tests and Results

Decoding Your Thyroid Tests and Results Decoding Your Thyroid Tests and Results Wondering about your thyroid test results? Learn about each test and what low, optimal, and high results may mean so you can work with your doctor to choose appropriate

More information

Differentiated Thyroid Carcinoma

Differentiated Thyroid Carcinoma Differentiated Thyroid Carcinoma The GOOD cancer? Jennifer Sipos, MD Associate Professor of Medicine Director, Benign Thyroid Program Division of Endocrinology, Diabetes and Metabolism The Ohio State University

More information

Mastering Thyroid Disorders. Douglas C. Bauer, MD UCSF Division of General Internal Medicine

Mastering Thyroid Disorders. Douglas C. Bauer, MD UCSF Division of General Internal Medicine Mastering Thyroid Disorders Douglas C. Bauer, MD UCSF Division of General Internal Medicine Cases 68 yr old female with new atrial fibrillation and no other findings except TSH=0.04, normal free T4 79

More information

DEVELOPMENT & STRUCTURE OF THYROID GLAND DR TATHEER ZAHRA ASSISTANT PROFESSOR ANATOMY

DEVELOPMENT & STRUCTURE OF THYROID GLAND DR TATHEER ZAHRA ASSISTANT PROFESSOR ANATOMY DEVELOPMENT & STRUCTURE OF THYROID GLAND DR TATHEER ZAHRA ASSISTANT PROFESSOR ANATOMY DEVELOPMENT OF THYROID Concept of pharyngeal arch 3 rd week 4 th week Adults 7 th week HISTOGENESIS OF THYROID GLAND

More information

WTC 2013 Panel Discussion: Minimal disease

WTC 2013 Panel Discussion: Minimal disease WTC 2013 Panel Discussion: Minimal disease Susan J. Mandel MD MPH Panelists Ken Ain Yasuhiro Ito Stephanie Lee Erich Sturgis Mark Urken Faculty/Presenter Disclosure Relationships with commercial interests

More information

Thyroid Nodules. Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA

Thyroid Nodules. Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA Thyroid Nodules ENDOCRINOLOGY DIVISION ENDOCRINOLOGY DIVISION Dr. HAKIMI, SpAK Dr. MELDA DELIANA, SpAK Dr. SISKA MAYASARI LUBIS, SpA Anatomical Considerations The Thyroid Nodule Congenital anomalies Thyroglossal

More information

Dharma Lindarto Div. Endokrin-Metabolisme dan Diabetes. Dep Ilmu Penyakit Dalam FK USU / RSUP HAM Medan

Dharma Lindarto Div. Endokrin-Metabolisme dan Diabetes. Dep Ilmu Penyakit Dalam FK USU / RSUP HAM Medan HYPERTHYROIDISM Dharma Lindarto Div. Endokrin-Metabolisme dan Diabetes. Dep Ilmu Penyakit Dalam FK USU / RSUP HAM Medan Anatomy of the Thyroid Gland Tiroid Disease Multi N Aspect fungtion morphology eutiroid,

More information

HYPERTHYROIDISM. Hypothalamus. Thyrotropin-releasing hormone (TRH) Anterior pituitary gland. Thyroid-stimulating hormone (TSH) Thyroid gland T4, T3

HYPERTHYROIDISM. Hypothalamus. Thyrotropin-releasing hormone (TRH) Anterior pituitary gland. Thyroid-stimulating hormone (TSH) Thyroid gland T4, T3 HYPERTHYROIDISM Hypothalamus Thyrotropin-releasing hormone (TRH) Anterior pituitary gland Thyroid-stimulating hormone (TSH) Thyroid gland T4, T3 In hyperthyroidism, there is an increased production of

More information

Gerard M. Doherty, MD

Gerard M. Doherty, MD Surgical Management of Differentiated Thyroid Cancer: Update on 2015 ATA Guidelines Gerard M. Doherty, MD Chair of Surgery Utley Professor of Surgery and Medicine Boston University Surgeon-in-Chief Boston

More information

Thyroid gland defects. Dr. Tara Husain

Thyroid gland defects. Dr. Tara Husain Thyroid gland defects Dr. Tara Husain Thyroid Pituitary Axis TRH secreted in the hypothalamus stimulates production and Secretion of TSH TSH stimulates secretion of T3,T4 T4 has negative feed back on secretion

More information

Objectives. How to Investigate Thyroid Nodules like A Pro

Objectives. How to Investigate Thyroid Nodules like A Pro How to Investigate Thyroid Nodules like A Pro Chris Sadler, MA, PA C, CDE, DFAAPA Medical Science Outcomes Liaison Intarcia Diabetes and Endocrine Associates La Jolla, CA Past President ASEPA Disclosures

More information

Approach to Thyroid Dysfunction in the Elderly

Approach to Thyroid Dysfunction in the Elderly Approach to Thyroid Dysfunction in the Elderly Fernando Melaragno Endocrinology Objective The objective of this lecture is to review the epidemiology, clinical presentation, risks and complications, and

More information

Case 4: Disseminated bone metastases from differentiated follicular thyroid cancer

Case 4: Disseminated bone metastases from differentiated follicular thyroid cancer Case 4: Disseminated bone metastases from differentiated follicular thyroid cancer Giuliano Mariani Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa (Italy) Disseminated bone

More information

Objectives. 1)To recall thyroid nodule ultrasound characteristics that increase the risk of malignancy

Objectives. 1)To recall thyroid nodule ultrasound characteristics that increase the risk of malignancy Evaluation and Management of Thyroid Nodules in Primary Care Chris Sadler, MA, PA C, CDE, DFAAPA Medical Science Outcomes Liaison Intarcia Diabetes and Endocrine Associates La Jolla, CA Past President

More information

Disorders of Thyroid Function

Disorders of Thyroid Function Disorders of Thyroid Function Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Thyroid Hormone Axis Hypothalamus TRH

More information

Thyroid Cancer & rhtsh: When and How?

Thyroid Cancer & rhtsh: When and How? Thyroid Cancer & rhtsh: When and How? 8 th Postgraduate Course in Endocrine Surgery Capsis Beach, Crete, September 21, 2006 Quan-Yang Duh, Professor of Surgery, UCSF Increasing Incidence of Thyroid Cancer

More information

Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer

Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer AACE - Advances in Medical and Surgical Management of Thyroid Cancer - 2018 Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel

More information

Southern Derbyshire Shared Care Pathology Guidelines. Hyperthyroidism

Southern Derbyshire Shared Care Pathology Guidelines. Hyperthyroidism Southern Derbyshire Shared Care Pathology Guidelines Hyperthyroidism Purpose of Guideline The management and referral criteria of patients with newly diagnosed hyperthyroidism. Background Hyperthyroidism

More information